Genetic Technologies 대차 대조표 상태

재무 상태 기준 확인 4/6

Genetic Technologies 의 총 주주 지분은 A$1.8M 이고 총 부채는 A$643.5K, 이는 부채 대 자기자본 비율을 35.2% 로 가져옵니다. 총자산과 총부채는 각각 A$6.2M 및 A$4.4M 입니다.

주요 정보

35.2%

부채 비율

AU$643.55k

부채

이자 보상 비율	n/a
현금	AU$1.04m
주식	AU$1.83m
총 부채	AU$4.36m
총 자산	AU$6.19m

최근 재무 상태 업데이트

Recent updates

Genetic Technologies Limited's (ASX:GTG) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 15

Should You Take Comfort From Insider Transactions At Genetic Technologies Limited (ASX:GTG)?

Dec 17

재무 상태 분석

단기부채: GTG 의 단기 자산 ( A$3.7M )은 단기 부채( A$4.2M ).

장기 부채: GTG 의 단기 자산( A$3.7M )이 장기 부채( A$160.6K ).

부채 대 자본 내역 및 분석

부채 수준: GTG 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: GTG 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 35.2% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: GTG 은 마지막 보고 무료 현금 흐름을 기준으로 1 개월 동안 충분한 현금 활주로를 보유하고 있지만 이후 추가 자본을 조달했다.

예측 현금 활주로: GTG 은 잉여현금흐름추정을 기준으로 1 개월 동안 충분한 현금 활주로를 확보할 것으로 예상되지만 이후 추가 자본을 조달했습니다.

Genetic Technologies 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

Genetic Technologies Receives Delisting Notification Letter from Nasdaq

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Recent updates

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

New major risk - Revenue and earnings growth

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Independent Non-Executive Chairman recently bought AU$80k worth of stock

New major risk - Financial position

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited's (ASX:GTG) CEO Will Probably Find It Hard To See A Huge Raise This Year

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Should You Take Comfort From Insider Transactions At Genetic Technologies Limited (ASX:GTG)?

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Receives Delisting Notification Letter from Nasdaq

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기